133 related articles for article (PubMed ID: 19819879)
1. Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium.
Van Brabandt H; Neyt M
Europace; 2009 Dec; 11(12):1571-3. PubMed ID: 19819879
[No Abstract] [Full Text] [Related]
2. Response to editorial: Pitfalls in economic analysis.
Cowie MR
Europace; 2010 Jul; 12(7):1044-6; author reply 1046-7. PubMed ID: 20478929
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of cardioverter-defibrillators in heart failure patients.
Gandjour A
Europace; 2009 Dec; 11(12):1721. PubMed ID: 19880854
[No Abstract] [Full Text] [Related]
4. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
5. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?
Bond M; Mealing S; Anderson R; Dean J; Stein K; Taylor RS
Int J Cardiol; 2009 Nov; 137(3):206-15. PubMed ID: 18703244
[TBL] [Abstract][Full Text] [Related]
6. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
8. Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
Huang DT; Sesselberg HW; McNitt S; Noyes K; Andrews ML; Hall WJ; Dick A; Daubert JP; Zareba W; Moss AJ;
J Cardiovasc Electrophysiol; 2007 Aug; 18(8):833-8. PubMed ID: 17537209
[TBL] [Abstract][Full Text] [Related]
9. Editorial: The economical challenge in the treatment of chronic heart failure: is primary prophylactic implantable cardioverter defibrillator therapy cost-effective in Europe?
Cowie MR
Europace; 2009 Oct; 11(10):1407-8; author reply 1408-10. PubMed ID: 19684038
[No Abstract] [Full Text] [Related]
10. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
11. Implantable cardioverter-defibrillator therapy and the total burden of sudden cardiac death.
Huikuri HV
Europace; 2009 Dec; 11(12):1574. PubMed ID: 19933771
[No Abstract] [Full Text] [Related]
12. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
[TBL] [Abstract][Full Text] [Related]
13. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
14. Obesity as a risk factor for sustained ventricular tachyarrhythmias in MADIT II patients.
Pietrasik G; Goldenberg I; McNitt S; Moss AJ; Zareba W
J Cardiovasc Electrophysiol; 2007 Feb; 18(2):181-4. PubMed ID: 17338766
[TBL] [Abstract][Full Text] [Related]
15. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction.
Goldenberg I; Moss AJ; McNitt S; Zareba W; Andrews ML; Hall WJ; Greenberg H; Case RB;
Am J Cardiol; 2006 Aug; 98(4):485-90. PubMed ID: 16893702
[TBL] [Abstract][Full Text] [Related]
16. Relation of body mass index to sudden cardiac death and the benefit of implantable cardioverter-defibrillator in patients with left ventricular dysfunction after healing of myocardial infarction.
Choy B; Hansen E; Moss AJ; McNitt S; Zareba W; Goldenberg I;
Am J Cardiol; 2010 Mar; 105(5):581-6. PubMed ID: 20185000
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic implantable cardioverter-defibrillator therapy in patients with left ventricular systolic dysfunction: a pooled analysis of 10 primary prevention trials.
Nanthakumar K; Epstein AE; Kay GN; Plumb VJ; Lee DS
J Am Coll Cardiol; 2004 Dec; 44(11):2166-72. PubMed ID: 15582314
[TBL] [Abstract][Full Text] [Related]
18. The economical challenge in the treatment of chronic heart failure: is primary prophylactic ICD therapy cost-effective in Europe?
Meine M; Smith T; Hauer RN
Europace; 2009 Jun; 11(6):689-91. PubMed ID: 19470592
[No Abstract] [Full Text] [Related]
19. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
[TBL] [Abstract][Full Text] [Related]
20. The implantable cardiac defibrillator--treatment at last for sudden cardiac death?
Hider P
N Z Med J; 1999 Mar; 112(1084):85-7. PubMed ID: 10210292
[No Abstract] [Full Text] [Related]
[Next] [New Search]
